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httpense.Abstract Background: Elevated admission plasma glucose is associated with increased mortality
in patients who are admitted with acute coronary syndromes.
Aim: To validate the hypothesis that tight glycemic control could reduce major adverse cardiac
events in hyperglycemic patients with acute coronary syndromes.
Methods: Fifty adult patients admitted with acute coronary syndromes within 6 h of presenta-
tion with ‘‘RBS > 140 mg/dl’’ were enrolled in this study to evaluate the effect of tight glycemic
control using insulin actrapid infusion (aiming at RBS of 80–130 mg/dl during the 1st 24 h post
admission) on decreasing infarct size, and major adverse cardiac events during ICU admission
and 30 days follow up.
Results: Of 50 patients enrolled in the study, 25 patients received insulin by infusion (group A),
while the rest received insulin via S.C. route (group B). The glycemic control was signiﬁcantly lower
in group A.
Heart failure at 7 and 30 days was 4% and 12%, respectively, in group A vs. 20% and 24%,
respectively, in group B. Hemodynamic instability was seen in 8% in group A vs. 28% in group
B during the ICU stay. Mortality at 7 and 30 days was 0% and 0%, respectively, for group A
vs. 4% and 12%, respectively, for group B.
Conclusion: Tight glycemic control in patients with acute coronary syndromes presenting with
hyperglycemia on admission is beneﬁcial.
 2012 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.o.com (R. El-Shenawy).
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The Euro Heart Survey Diabetes 2007 examined the correla-
tion between acute coronary syndromes and diabetes. It has
provided evidence that diabetes is particularly common in pa-
tients with chest pain in the intensive coronary care unit
(ICCU). Patients with a normal blood glucose level accountuction and hosting by Elsevier B.V.
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6 R. El-Shenawy et al.for only one third of the patients admitted to the ICCU. An-
other third is made up patients with known diabetes, whereas
the remaining patients have newly diagnosed diabetes, i.e.
diagnosed on admission, or an impaired glucose tolerance [1].
The world prevalence of diabetes among adults (aged 20–
79 years) is approximately 6.4%, affecting 285 million adults
in 2010 and is predicted to rise to 7.7%, affecting 439 million
adults by 2030. Between 2010 and 2030, there will be a 69%
increase in number of adults with diabetes in developing coun-
tries and a 20% increase in developed countries. Globally, dia-
betes is likely to be the ﬁfth leading cause of death [2].
With CHD ranking as the number one cause of death
worldwide, with diabetes increasing by two to three times the
risk of CHD, and with diabetes and the often preceding meta-
bolic syndrome dramatically increasing their prevalence, dia-
betologists and cardiologists have started to join their forces
to improve the management of the millions of patients suffer-
ing from both diseases [3].
Aim of the work
This study was designed to validate the hypothesis that inten-
sive blood glucose control with intravenous insulin infusion
could reduce short term in hospital mortality and 30 day mor-
tality, re-infarction, stroke and re-hospitalization for conges-
tive heart failure in critically ill hyperglycemic patients
admitted to an intensive care unit (ICU) with acute coronary
syndrome.
Patients and methods
Fifty critically ill adult patients admitted to the ICU with acute
coronary syndromes within 6 h of presentation with admission
hyperglycemia ‘‘RBS > 140 mg/dl’’ with or without previously
known diabetes mellitus were enrolled in this study.
Patients were divided into two groups; 25 patients in each
group, where group A received intensive insulin therapy in
the form of insulin infusion for 24 h in order to maintain blood
glucose in the range of 80–130 mg/dl.
Patients in group B received reperfusion therapy with the
standard anti ischemic therapy and standard glycemic control
with sliding scale insulin if glucose exceeded 180 mg/dl, target-
ing in hospital glycemic control with blood glucose < 140 mg/
dl.
Full history taking, clinical examination, ECG analysis
quantitatively and qualitatively, cardiac enzymes serial analy-
sis, transthoracic two-dimensional, M-mode and color ﬂow
Doppler imaging echocardiography was done before discharge
stressing on the following: segmental wall motion abnormali-
ties (SWMA) with calculation of segmental wall motion score
and on left ventricular ejection fraction (calculated by two-
dimensional echocardiography using modiﬁed Simpson’s
method).
Random blood sugar was measured hourly and corrected
accordingly with modulation of the dose of insulin infusion
for group A in order to achieve the targeted level of glycemic
control between 80 and 130 mg/dl. Serum K was repeated
every 2 h and as needed according to the assessment of the
attending physician in order to avoid incidence of hypokalemia
and hypoglycemia and in order to treat accordingly. Then in
hospital glycemic control was maintained by sliding scale sub-cutaneous insulin four times daily in order to maintain this le-
vel of tight glycemic control along with reperfusion therapy
with the standard anti ischemic therapy as well.
All patients were closely monitored for the incidence of in
hospital complications in the form of in-hospital death, re-
infarction, arrhythmias, heart failure or hemodynamic insta-
bility or stroke.
Incidence of out of hospital mortality, re-infarction, heart
failure and any coincident complication was followed up for
1 month.
Results
Comparison between studied groups regarding that demo-
graphic data revealed that there was no signiﬁcant difference
in the proportions between male and females in both groups
(Table 1).
Mean age was 55.12 ± 8.03 for group A and 59.68 ± 11
for group B with non-signiﬁcant difference as shown in
Table 1.
Each group was composed of 25 patients of whom eight
(32%) patients were diagnosed as having: non ST-segment ele-
vation acute coronary syndromes ‘‘Unstable angina + Non
STEMI’’, 10 (40) patients were diagnosed as having inf. STE-
MI’’, seven (28%) patients were diagnosed as having anterior
STEMI. Both groups were identical regarding diagnosis as
shown in Table 2.
The aim of tight glycemic control in the intensive insulin
therapy arm group A was successfully achieved. The range
of glycemic control during the 1st 24 h as well as during the
rest of ICU stay was signiﬁcantly lower in group A (Table 3
and Fig. 1).
Cardiac enzymes: There was no signiﬁcant difference
regarding CK-MB on admission, but after 12 h it was insignif-
icantly higher in group B. There was no signiﬁcant difference
between both groups regarding troponin on admission,
although the number of cases converting to positive being
higher in group B as shown in Table 4, Figs. 2 and 3.
The ECG was qualitatively and quantitatively analyzed for
each patient in both groups and comparison between both
groups at admission and at 24 h from admission and upon dis-
charge showed no signiﬁcant difference between studied
groups regarding most of the ECG variables but the sum of
ST-segment depression in inferior leads was signiﬁcantly high-
er in group B at ECGs done 24 h after admission and the sum
of ST-segment elevation in I and aVL at discharge was higher
in group B (Table 5 and Fig. 4).
Echocardiographic parameters: E.F was higher in group A
yet the difference did not reach statistical signiﬁcance, whereas
regional wall motion abnormality score index was signiﬁcantly
lower in group A as shown in Table 6.
In our study; there was no signiﬁcant difference between the
studied groups regarding the incidence of re-infarction
where only one case in group B suffered from re-infarction
while no cases in group A. The incidence of heart failure was
higher in group B; ﬁve cases (20%) compared to only one case
(4%) in group A (P value 0.08) (Table 7).
During 30 days follow up of patients in both groups,
there was a non-signiﬁcant increase in the incidence of heart
failure in group B compared to group A (3 vs. 6, P value
0.27). There was an insigniﬁcant increase in the incidence of
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Figure 1 Comparison between studied groups regarding the range of the 1st 24 h glycemic control and range of glycemic control during
the rest ICU stay.
Table 1 Comparison between studied groups regarding demographic data.
Demographic data G A (n= 25) G B (n= 25) X2 P-value
No % No %
Male 18 72 14 56
Female 7 28 11 44 1.39 0.24
Age in years (mean ± SD) 55.12 ± 8.03 59.68 ± 11 1.67a 0.1
a T-test.
Table 2 Comparison between studied groups regarding diagnosis.
Diagnosis G A (n= 25) G B (n= 25)
No % No %
Unstable angina 8 32 8 32
Acute inferior STEMI 10 40 10 40
Acute extensive anterior STEMI with lateral extension 7 28 7 28
Tight Glycemic control in acute coronary syndromes: Prognostic implications 7out of hospital mortality in group B (three cases 12% vs. no
cases in group A) as shown in Table 8.
The incidence of major adverse cardiac events was lower in
group A but the level was not signiﬁcant (6 vs. 10, P value
0.23) as shown in Table 9.
The presence of major adverse cardiac events was lower in
case of good glycemic control in both groups regardless of the
use of insulin infusion as shown in Table 10.
Discussion
The main role of insulin in the heart under physiological con-
ditions is obviously the regulation of substrate utilization. In-
deed, insulin promotes glucose uptake and its utilization via
glycolysis. Insulin, promoting glucose as the main cardiac en-
ergy substrate, reduces myocardial O2 consumption and in-
creases cardiac efﬁciency [4].Moreover, insulin seems to augment cardiomyocyte con-
traction, while it affects favorably myocardial relaxation, in-
creases ribosomal biogenesis and protein synthesis, stimulates
vascular endothelial growth factor (VEGF) and thereby angi-
ogenesis, suppresses apoptosis, promotes cell survival and ﬁ-
nally ameliorates both myocardial microcirculation and
coronary artery resistance, leading to increased blood perfu-
sion of myocardium. Thus, insulin acts directly on heart mus-
cle, and this action is mediated principally through PKB/Akt
signal pathway [5].
Under pathological conditions, such as type 2 diabetes,
myocardial ischemia, and cardiac hypertrophy, insulin signal
transduction pathways and action are clearly modiﬁed [6].
It should be noted that the anti-apoptotic and anti-inﬂam-
matory effects of insulin are attenuated in the presence of insu-
lin resistance; moreover, evidence suggests that myocardial
ischemia especially in the presence of hyperglycemia is
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Figure 2 Comparison between studied groups regarding CK-MB on admission and after 12 h.
Table 4 Comparison between studied groups regarding troponin and CK-MB.
Parameter G A (n= 25) G B (n= 25) X2 P-value
No % No %
CK-MB Admission 29.47 ± 28.13 34.62 ± 36.04 0.61a 0.54
After 12 h 68.24 ± 51.89 90.28 ± 84.77 0.39a 0.69
ve troponin On admission 16 64 16 64
+ve troponin 9 36 9 36
ve troponin After 12 h 7 28 2 8 3.39 0.06
+ve troponin 18 72 23 92
a U test =Mann–Whitney test.
Table 3 Comparison between studied groups regarding range of glycemic control.
Parameter G A (n= 25) mean ± SD G B (n= 25) mean ± SD T-test P-value
Range of 1st 24 h glycemic control (min) 81.64 ± 6.65 158.56 ± 47.86 7.96 <0.001
(max) 167.08 ± 60.87 281.16 ± 82.09 4.87a <0.001
Insulin dose in 1st 24 h 64.12 ± 26.23 50.4 ± 25.53 1.74a 0.08
Range of glycemic control during the rest of ICU stay (min) 108.08 ± 21.78 131.8 ± 50.45 2.04a 0.04
(max) 190.2 ± 57.11 301.96 ± 71.56 6.1 <0.001
a U test =Mann–Whitney test.
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8 R. El-Shenawy et al.associated with an important insulin resistance. Therefore, it is
conceivable that the beneﬁcial effects of insulin during myocar-
dial infarction in the presence of hyperglycemia are attenuated
[7].
The direct effects of endogenous or infused insulin and the
effects of preventing hyperglycemia on cardiac changes of
apoptosis and inﬂammation cannot be differentiated because
both occurred concomitantly [8].
In our study, there was a signiﬁcant difference in glycemic
control during the 1st 24 h and during the rest of ICU stay
with RBS being signiﬁcantly higher in group B which is of spe-
cial importance taking into account the results of a recent pro-
spective study that conﬁrms that: a persistent increase of
fasting glucose during hospitalization for acute myocardial
infarction has greater prognostic effect than baseline fasting
glucose. Changes in fasting glucose during hospitalization
Table 5 Comparison between studied groups regarding ECG 24 h after admission.
Parameters G A (n= 25)
Mean ± SD
G B (n= 25)
Mean ± SD
U-test P-value
Heart rate after 24 h 76.88 ± 17.2 77.56 ± 15.04 0.14 0.88
QRS duration after 24 h 77.2 ± 9.79 80.4 ± 11.72 1.04 0.30
No. of leads with TWI 3.16 ± 3.09 4.48 ± 3.16 1.32 0.18
No. of leads with STE 1.96 ± 2.09 1.92 ± 1.91 0.1 0.92
No. of leads with STD 1.68 ± 2.01 1.88 ± 2.11 0.33 0.74
No. of leads with abnormal Q waves 2.4 ± 2.65 2.2 ± 2.08 0.13 0.89
Sum of STD in 11 leads 1.46 ± 1.94 1.78 ± 2.41 0.33 0.74
Sum of ant STE 1.36 ± 2.3 0.94 ± 1.89 0.49 0.62
Sum of ant STD 0.26 ± 0.72 0.14 ± 0.45 0.45 0.65
Sum of STE V4-V6 0.42 ± 1.31 0.22 ± 0.46 0.23 0.82
Sum of STD V4-V6 0.74 ± 1.31 0.88 ± 1.76 0.06 0.95
Sum of STE in inf leads 0.6 ± 0.97 0.78 ± 1028 0.35 0.73
Sum of STD in inf leads 0.1 ± 0.5 0.4 ± 0.89 1.98 0.04
Sum of STE in I, aVL 0.02 ± 0.1 0.14 ± 0.42 1.42 0.15
Sum of STD in lead I, aVL 0.36 ± 0.57 0.36 ± 0.62 0.19 0.84
U test =Mann–Whitney test.
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term mortality risk [9].
Meijering et al. evaluated insulin protocols in 24 studies
(including six with AMI patients). The best results were found
using a dynamic scale protocol for continuous intravenous
insulin infusion, combined with frequent blood glucose mea-
surement and taking into account changes in glucose levels
rather than single values [10]. And that was similar to the pro-
tocol we used during our study.
As for cardiac enzymes in our study while there was no sig-
niﬁcant difference regarding CK-MB on admission it was high-Table 6 Comparison between studied groups regarding Echo.
Echo G A (n= 25
Mean ± SD
IVS 9.84 ± 0.89
PW 10 ± 1
LVED 50.24 ± 4.31
LVES 37.24 ± 4.28
Aorta 24.86 ± 2.67
LA 40.96 ± 4.39
FS 29.88 ± 4.99
EF 56 ± 8.02
Regional wall motion abnormality score index 4.6 ± 3.63
U test =Mann–Whitney test.er in group B after 12 h. There was no difference between both
groups regarding troponin on admission; with the number of
cases converting to positive being higher in group B.
This is in agreement with the study by Raffaele Marfella at
2009 that showed that hyperglycemia was associated with
higher troponin I levels and larger infarct size as well as myo-
cardial TNF-a, NFjB-activated, caspase-3, and nitrotyrosine
levels compared with normoglycemic patients [11].
In our study; E.F was lower in group B but statistically
non-signiﬁcant. Regional wall motion abnormality score index
was highly signiﬁcantly lower in group A.
This is in agreement with a study by Raffaele Marfella that
demonstrated that the reduction in glucose levels in the ﬁrst
period after AMI might improve cardiac function. After
adjusting for baseline glucose and other clinical predictors,
they found that, for every 10-mg/dl drop in glucose level be-
tween baseline and 6 days, there was an 11% relative decrease
in the infarct segment length, 13% in the troponin levels, 11%
in the wall motion scores, and a 12% decrease in the MPI as
well as an 11% relative increase in the ejection fraction in
hyperglycemic patients [11].
In our study; there was no signiﬁcant difference between the
studied groups regarding the incidence of re-infarction while
only one case in group B suffered from re-infarction vs. no) G B (n= 25)
Mean ± SD
T-test P-value
9.8 ± 1.66 0.11 0.92
10.02 ± 2.12 0.04 0.97
52.04 ± 5.4 1.3 0.19
36.84 ± 5.87 0.27 0.78
25.28 ± 4.11 0.43 0.67
41.16 ± 5.84 0.14 0.89
28.56 ± 3.91 1.04 0.3
52.48 ± 7.48 1.6 0.12
10.48 ± 6.12 3.39 <0.001
Table 9 Statistical comparison between the studied groups as regarding the major adverse cardiac events.
The major adverse cardiac events The studied groups Test of signiﬁcance P value
Group A
No= 25
Group B
No = 25
No % No % v2
Present 6 24 10 40 1.47 0.23
Absent 19 76 15 60
Table 8 Comparison between studied groups regarding out of hospital complications.
Out of hospital complications G A (n= 25) G B (n= 25) X2 P-value
No % No %
Re-infarction 0 0 1 4 1.02 0.31
HF 3 12 6 24 1.22 0.27
Death 0 0 3 12 3.19 0.07
Others 0 0 2 8 1.39 0.2
Cerebral hemorrhage and renal impairment 0 0 1 4 1.02 0.31
U test =Mann–Whitney test.
Table 10 Statistical comparison between glycemic control during the 1st 24 h and the incidence of major adverse cardiac events.
The major adverse cardiac events Mann–Whitney U-test P value
Present
No = 16
Absent
No = 34
Maximal glycemic control during the 1st 24 h
Mean ± SD
245.1 ± 100.9 214.3 ± 87.1 0.85 0.39
Minimal glycemic control during the 1st 24 h
Mean ± SD
141.9 ± 68.3 109.9 ± 38.5 1.10 0.27
Table 7 Comparison between studied groups regarding in-hospital complications.
In-hospital complications G A (n= 25) G B (n= 25) X2 P-value
No % No %
Arrhythmias 11 44 11 44 <0.05
Sinus bradycardia 4 16 3 12 <0.05
Sinus tachycardia 0 0 3 12 <0.05
Infrequent PVCs 3 12 0 0 <0.05
Infrequent PVCs and PACs 2 8 1 4 <0.05
Multifocal atrial tachycardia 1 4 0 0 <0.05
AF 1 4 2 8 13.14 0.28
Ventricular bigmeny 1 4 2 8 <0.05
Non sustained VT 2 8 0 0 <0.05
Accelerated idioventricular rhythm 0 0 1 4 <0.05
Wenckeback phenomenon 0 0 1 4 <0.05
Frequent PACs 0 0 1 4 <0.05
Re-infarction 0 0 1 4 1.02 0.31
Heart failure 1 4 5 20 3.03 0.08
Hemodynamic instability 2 8 7 28 3.39 0.06
Death 0 0 1 4 1.02 0.31
U test =Mann–Whitney test.
10 R. El-Shenawy et al.cases in group A. The incidence of heart failure was higher in
group B; ﬁve cases (20%) in comparison to only one case (4%)
in group A (P value 0.08).In accordance with these data, the HI-5 (Hyperglycemia
Intensive Insulin Infusion in Infarction) study evidenced that,
although insulin infusion therapy did not reduce the primary
Tight Glycemic control in acute coronary syndromes: Prognostic implications 11end point of mortality, it did reduce the secondary end points
of heart failure (12.7%) compared with control subjects
(22.8%; P= 0.04) as well as re-infarction at 3 months (2.4%
vs. 6.1%; P= 0.05) [12]. In our study; the incidence of hemo-
dynamic instability during the ICU stay was near signiﬁcantly
higher in group B (7 cases 28% vs. 2 cases 8%, P value 0.06) in
group A.
This again is in agreement with the study by Raffaele Mar-
fella which evidenced that tight glycemic control in the imme-
diate post-infarcted period, for almost 3 days, was associated
with signiﬁcantly less need for inotropic support and lower
incidence of atrial ﬁbrillation and pneumonia [11]. In our
study, no cases suffered from cerebrovascular accidents in
the two groups. Only one case in group B suffered from death
during the ICU stay. But during 30 days follow up of patients
in both groups, there was lower incidence of heart failure;
(three cases 12% vs. six cases 24%, P value 0.27) in group A.
This again is in agreement with the HI-5 (Hyperglycemia
Intensive Insulin Infusion in Infarction) study [12]. In our
study, there was no signiﬁcant difference regarding the inci-
dence of other complications with the incidence of renal
impairment in one case in group B vs. no cases in group A.
There was only one case of cerebral hemorrhage in group B
vs. no cases in group A.
In our study, there was a trend in the incidence of out of
hospital mortality in group B (three cases 12% vs. no cases)
in group A.
This again is in agreement with the more recent HI-5 study
did ﬁnd a lower mortality at 3 and 6 months in favor of inten-
sive glucose lowering, which is consistent with DIGAMI-1,
although this was not statistically signiﬁcant. The mortality
rates in the HI-5 study were markedly lower than those in
the DIGAMI studies [12].
In a study by Raffaele Marfella, although the investigators
did not observe a signiﬁcant reduction in overall mortality in
patients receiving the insulin infusion, they suggested that ‘‘it re-
mains possible that tight glycemic control with insulin therapy
after acute myocardial infarction improves outcomes.’’ [11].
Two other studies support the concept that glucose control
matters in diabetic patients with CVD. In the Munich registry,
optimization of care in diabetic patients with AMI was inves-
tigated. Part of the intervention studied was an I.V. insulin
infusion aiming at normalizing hyperglycemia within 12 h.
In-hospital mortality in diabetic patients with ACS dropped
from 29% to 17% with optimized care [13].
Data from MINAP (observational Myocardial Infarction
National Audit Project) show that patients without known
diabetes, presenting with ACS and admission glucose
>11 mmol/L treated with intravenous insulin have a mortality
rate approximately 50% lower than similar patients not receiv-
ing insulin. Thus, contemporary evidence suggests that in-
creased blood glucose in acute MI patients with or without
diabetes is associated with a worse outcome and that insulin
treatment may be associated with reduced mortality [14].
Similarly, the CARDINAL trial database, showed that in
non-diabetic patients, higher baseline glucose predicted higher
mortality [hazards ratio (HR) 1.12, per 0.6 mmol/L (11 mg/
dL) increase], and a greater 24 h change in glucose predicted
lower mortality (HR 0.91, for every 0.6 mmol/L drop in glu-
cose in the ﬁrst 24 h) at 30 days. At multivariable analysis,
baseline glucose and 24 h changes remained signiﬁcant mortal-
ity predictors at 180 days in non-diabetic patients. However,using a multivariable 30-day mortality model, neither baseline
glucose nor the 24 h change in glucose predicted mortality in
diabetic patients [15].
Accordingly, the epidemiological analysis from the
DIGAMI-2 study [16] together with information from the
study on patients in intensive care by van den Berghe strongly
support the concept that a meticulous glucose control rather
than insulin treatment or the insulin dose might be an impor-
tant factor to improve cardiac outcome in hyperglycemic pa-
tients [17].
Conclusion
The data from our study support the hypothesis that tight gly-
cemic control in patients with acute coronary syndrome pre-
senting with hyperglycemia at admission whether known or
not known to be diabetic is beneﬁcial in reducing both in hos-
pital and out of hospital incidence of complications especially
heart failure and hemodynamic instability with a decrease in
wall motion score index and some improvement in the ejection
fraction at echocardiography examination. The incidence of
mortality was also lower in the group of better glycemic con-
trol although not statistically signiﬁcant.
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